Previous meta-analyses reported that in early stage ovarian cancer, diagnostic performances of CA125, HE4, and ROMA score were relatively lower than those in advanced stage ovarian cancer (Li et al., 2012; Dayyani et al., 2016). This evidence concerns the gene MUC16 and ovarian cancer.